A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer

This study is testing a drug called WSD0922-FU in people with advanced non-small cell lung cancer (NSCLC) that has a specific type of mutation in the EGFR gene, and whose cancer has progressed after treatment with an EGFR-targeting drug (called a TKI). **You may be eligible if...** - You are between 18 and 75 years old - You have locally advanced or metastatic non-small cell lung cancer confirmed by biopsy - Your tumor has a known EGFR-sensitizing mutation - You have progressed on one prior EGFR TKI treatment (not more than one) - You have at least one measurable tumor on scans - Your overall health score (ECOG) is 0 or 1 **You may NOT be eligible if...** - You have had more than one prior EGFR TKI treatment - You have active brain metastases - You have significant heart disease, interstitial lung disease, or active infections - You are pregnant or breastfeeding - You are HIV positive or have a positive syphilis test Talk to your doctor to see if this trial is right for you.